Pulmonary Edema Therapeutics Market Size
The global pulmonary edema therapeutics market was valued at approximately USD 3.8 billion in 2025 and is projected to reach nearly USD 6.2 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033.
The market is witnessing steady growth driven by the increasing prevalence of cardiovascular diseases, congestive heart failure, acute respiratory disorders, and kidney related complications associated with pulmonary edema. Rising demand for rapid acting diuretics, vasodilators, oxygen therapy, and advanced critical care management solutions is significantly supporting market expansion globally. In addition, increasing hospitalization rates for cardiac and pulmonary emergencies, growing geriatric population, and advancements in intensive care treatment protocols are improving patient outcomes and accelerating adoption of pulmonary edema therapeutics across healthcare systems.
The market is also benefiting from continuous regulatory approvals, expanding emergency care infrastructure, and increasing investments in cardiovascular and respiratory disease research by pharmaceutical companies. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to support development of innovative cardiopulmonary therapies through accelerated approval pathways and updated treatment guidelines. Companies including Novartis AG, Pfizer Inc., AstraZeneca PLC, and Baxter International Inc. are actively focusing on advanced diuretic therapies, cardiopulmonary drugs, and critical care treatment solutions to strengthen their global market presence. Furthermore, increasing adoption of noninvasive ventilation systems, digital patient monitoring technologies, and personalized cardiovascular treatment approaches are creating substantial growth opportunities for the pulmonary edema therapeutics market worldwide.
Pulmonary Edema Therapeutics Market Dynamics
Increasing biomarkers to diagnose Pulmonary Edema is expected to drive market growth.
Biomarkers to diagnose pulmonary edema are becoming more common in recent diagnostic evaluations. A biomarker is a detectable sign of a particular biological state or situation, like a disease process. Clinical examination and imaging testing are the most prevalent procedures for diagnosing pulmonary edema. Blood tests are also useful for detecting disease by looking for biomarkers in the blood. Biomarkers are less expensive than other types of evaluation tests.
Also, these devices can identify other cardiac or kidney disorders. Moreover, the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension has increased the demand for therapeutics. Thus, the market is expected to drive in the forecast period.
Pulmonary Edema Therapeutics Market Segment Analysis
Cardiogenic pulmonary edema segment is expected to hold the largest market share in pulmonary edema therapeutics market
The cardiogenic pulmonary edema segment is expected to dominate in 2020. The segment benefits because it is most common, and increased pressures in the heart cause it. It's usually a result of heart failure. When a diseased or overworked left ventricle can't pump out enough of the blood it gets from your lungs, pressures in the heart go up. The increased pressure pushes fluid through the blood vessel walls into the air sacs. The medical conditions that can cause heart failure and lead to pulmonary edema include Coronary artery disease, Cardiomyopathy, Heart valve problems, High blood pressure (hypertension), and other heart problems cause it. Therefore, it has increased the demand for the treatment, due to which the market segment is expected to hold the largest market share in the forecast period.
Pulmonary Edema Therapeutics Market Scope and Summary
| Metrics | Details |
| Market CAGR | 3.3% |
| Segments Covered | By Drug Class, By Type, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Pulmonary Edema Therapeutics Market Geographical Analysis
North America region holds the largest market share in the global pulmonary edema therapeutics market
In 2025, North America accounted for the highest revenue share. The increasing prevalence of pulmonary edema, rising geriatric population, well-established infrastructure, rising health care investments and rising affordability of drugs, product launches and collaborations by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Pulmonary edema commonly affects individuals older than 65 years of age. Males are more commonly affected by pulmonary edema than a woman. More than a million Americans are diagnosed with pulmonary edema each year, yet many people don't know the condition or whether they're at risk. Moreover, On May 8, 2020, Amgen Inc. and Cytokinetics Inc. announced that the US Food and Drug Administration (FDA) had granted omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as cardiac myotrope, Fast Track designation for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Key Developments
February 2026: Rising adoption of advanced diuretics, non-invasive ventilation systems, and AI-enabled respiratory monitoring technologies accelerated growth in the pulmonary edema therapeutics market across North America and Europe. Major companies including Pfizer Inc., Novartis AG, AstraZeneca plc, and ResMed expanded innovation in cardiopulmonary care solutions.
January 2026: Increasing prevalence of cardiovascular diseases, heart failure, and acute respiratory disorders across the United States, China, India, Germany, and Japan strengthened demand for advanced pulmonary edema treatment solutions. Asia-Pacific emerged as the fastest growing regional market driven by rising chronic disease burden and expanding healthcare infrastructure.
December 2025: Growing adoption of loop diuretics, vasodilators, oxygen therapy, and ventilatory support systems improved emergency and long-term pulmonary edema management globally. Hospitals strengthened integration of intensive cardiopulmonary monitoring technologies.
November 2025: Expansion of tele-critical care and remote respiratory monitoring platforms across Europe and North America improved accessibility to pulmonary edema diagnosis and treatment services. Healthcare providers increasingly integrated AI-assisted patient monitoring and digital pulmonary care systems.
October 2025: Rising advancements in biomarker-based cardiac diagnostics, portable ventilators, and precision respiratory therapies improved treatment accuracy and patient outcomes globally. Research institutions accelerated innovation in targeted therapies for acute pulmonary conditions.
September 2025: Increasing collaborations between pharmaceutical companies, respiratory device manufacturers, and healthcare organizations accelerated clinical research initiatives for pulmonary edema therapeutics worldwide. Europe and Asia-Pacific strengthened investments in emergency respiratory care infrastructure.
August 2025: Growing healthcare investments and awareness regarding acute respiratory and cardiac disorders improved accessibility to pulmonary edema therapeutics across Middle East, Latin America, and Asia-Pacific regions. Governments expanded critical care and emergency medicine programs.
July 2025: Rising demand for home-based respiratory care, portable oxygen therapy, and connected ventilation systems improved long-term pulmonary edema management globally. Companies including Philips Healthcare and GE HealthCare strengthened innovation in digital respiratory support technologies.
June 2025: Increasing focus on critical care management, cardiopulmonary disease prevention, and advanced respiratory therapeutics supported strong growth in the pulmonary edema therapeutics market worldwide. North America maintained market leadership due to advanced intensive care infrastructure, while Asia-Pacific recorded rapid growth driven by increasing healthcare modernization and rising cardiovascular disease prevalence.
Pulmonary Edema Therapeutics Market Competitive Landscape
Major key players in the pulmonary edema therapeutics market are Pfizer Inc., sanofi-aventis U.S. LLC, Purdue Phanna L.P., Evus Pharmaceuticals, LLC , NovaDel Pharma Inc., American Regent, Inc., Medicure Inc. and Copperhead Chemical Company.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Product Portfolio:
FUROSEMIDE (furosemide): Furosemide belongs to a group of medicines called loop diuretics (also known as water pills). It is given to help treat fluid retention (edema) and swelling caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.
